Gene therapy for lung inflammatory diseases: not so far away?

Citation for published version:

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Thorax

Publisher Rights Statement:
available via europepmc open access link

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Gene therapy for lung inflammatory diseases: not so far away?

Jean-Michel Sallenave, David J Porteous, Christopher Haslett

Abstract
The lung is a readily accessible target organ for gene therapy. To date, therapeutic gene delivery has largely focused on introducing functional, corrective genes in lung diseases arising from single gene defects such as cystic fibrosis. More recently interest has centred on gene therapy as a potential therapeutic tool in modulating complex pathological processes such as pulmonary inflammation. Genetic modification of critical components of the inflammatory process may be beneficial – for example, overexpressing anti-elastase genes may circumvent elastase mediated lung damage in emphysema. With the development of improved viral and liposome vectors and the evolution of effective adjuvant immunosuppression to obviate host immune responses – for example, using selective cytokines and blockers of T cell surface activation – the potential exists to target therapeutic doses of transgene to deficient or dysregulated cells. Furthermore, increased understanding of tissuespecific promoter regions and of mechanisms controlling regulation of gene expression offer the potential for close control of therapeutic gene expression within the lung. Continuing refinements in these technologies will provide new therapeutic strategies in inflammatory lung disease.

Keywords: gene therapy, adenovirus, liposomes, elastase, elastase inhibitors.

The aim of somatic gene therapy is to replace, modify, or suppress the genes considered responsible for a given disease process. The lung is a particularly attractive organ for gene therapy because of its accessibility via the airways or the vasculature. Cystic fibrosis and α₁-antitrypsin (α₁AT) deficiency are the two most common fatal single gene defects affecting the lung in the Western world. The genetic abnormalities in these conditions have been well characterised and led to these diseases becoming the first logical targets for lung-directed gene therapy. Indeed, several trials of specific gene replacement (using the adenovirus vector for gene carriage in the USA and liposome vectors in the UK) have shown promising results.¹⁻³ The advances made in these areas have prompted interest in the role of gene therapy as a means of positively influencing more complex pulmonary disorders such as inflammatory lung diseases which might appear at first sight to be less amenable to genetic intervention. We shall confine our discussion to the potential application of gene therapy in inflammatory lung diseases (as an example of complex disease processes in the lung); however, it should be noted that far-reaching and promising advances have been made in applying gene therapy to, for example, lung tumours and HIV infection.

Scientific basis

WHICH LUNG DISEASES MAY BE AMENABLE TO GENE THERAPY?
To date over 100 clinical trials of gene therapy for cancer have been conducted and reported, as well as 12 trials assessing gene therapy for HIV and a further 21 for single gene defects (mostly cystic fibrosis and α₁AT deficiency). However, as far as we are aware, no trials have assessed gene therapy for inflammatory lung diseases such as chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDS), and asthma.

The prevailing hypothesis is that inflammatory conditions such as COPD and ARDS arise from an imbalance between potentially injurious inflammatory agents (for example, neutrophil-derived elastase and reactive oxygen species) and tissue protective mechanisms. Much is now known about mechanisms of tissue defence and cytoprotection in these conditions, leading to our interest in the manipulation of these processes by gene therapy.

WHICH VECTORS ARE MOST APPROPRIATE IN TARGETING THE LUNG?
The main technical hurdle to be overcome is delivering the appropriate gene to the nucleus using a vector associated with minimal toxicity and maximal efficacy.

The armamentarium of vectors for gene delivery includes liposomes, viral vectors (retrovirus, adenovirus, vaccinia, herpes virus, and adeno-associated virus⁴), and molecular conjugates.¹ In the context of the lung, liposomes and adenoviruses are particularly attractive. Cationic liposomes, while causing little or no...
Gene therapy for lung inflammatory diseases

achieved by the use of conventional immuno-suppressive drugs such as corticosteroids, cyclosporin, or FK506 or, more specifically, by using cytokines such as interleukin (IL)-12 which decreases neutralising IgA in the respiratory tract by switching off the CD4+ Th2 response and by blocking co-stimulatory receptors on antigen presenting cells and lymphocytes such as B7/CD28 and CD40/CD40 ligand, thus reducing lymphocyte activation. Such approaches allow both sustained expression and safe repeated administration of the transgene.

Further attempts to reduce host inflammatory responses and to enhance cell specificity and nuclear targeting are the focus of considerable research, and removal of the major hurdles toward effective, repeated gene therapy are keenly anticipated.

Therapeutic potential

The process of pulmonary inflammation is initiated by the stimulation of sequential migration of inflammatory cells from the circulation into the lung. Many pro-inflammatory molecules are potential targets for gene therapy. The influx of inflammatory cells could be prevented by counteracting the effects of selected cytokines and chemokines. For example, in situations where the “early” cytokines IL-1 and tumour necrosis factor (TNF) have been associated with adverse effects (such as in sepsis), overexpression of IL-1 receptor antagonist and soluble TNF receptor might be beneficial. Chemokines such as IL-8, responsible for the influx of neutrophils in ARDS, could be targeted using specific antisense DNA.

Protection against HNE could be provided by gene therapy using, for example, adenovirus (AD) and liposomes (LIP) to deliver genes for elastase inhibitors such as α1 proteinase inhibitor, secretory leucocyte proteinase inhibitor, or elastin (εN). Both the airway epithelium and the vasculature endothelium represent potential targets for gene therapy.

inflammation when administered in vivo, are in general poor gene transducers compared with adenoviruses. The latter have the opposite characteristics in that gene transduction is efficient (by virtue of mechanisms avoiding lysosomal degradation and promoting transfer to the nucleus) but significant inflammation and a specific immune response are induced in vivo.

Addition of specific peptides (growth factors, hormones, receptor ligands, or monoclonal antibodies) to liposome formulations can confer cell-specific targeting. Furthermore, the poor transducing capability of liposomes can be addressed by increasing nuclear tropism using nuclear localisation signals. Reduction of the pro-inflammatory and immunogenic properties of adenovirus vectors has been approached mainly by deleting some or all of the adenovirus genes and by manipulating the host immune response. The latter can be approached mainly by deleting some or all of the adenovirus genes and by manipulating the host immune response.

For the approaches discussed to be successful in obviating lung inflammation, careful planning of the timing and duration of gene therapy will be vital. It will therefore be necessary to introduce mechanisms capable of “switching on” and “switching off” therapeutic genes. One such mechanism attracting attention involves the use of inducible promoters for expression of selected genes. Examples of such promoters include the heat shock, tetracycline- and
steroid-responsive promoters. Furthermore, the use of lung-specific promoters such as surfactant protein C or Clara cell 10 kDa promoters will ensure tissue-specific expression of therapeutic genes.

While there are clearly several attractions in aiming to attenuate the transmigration of inflammatory cells into tissues, a more effective and possibly safer strategy may be to inactivate the potentially deleterious enzymes and reactive oxygen species liberated by effector cells in situ. Animal models of pulmonary inflammation have clearly implicated the overexpression of elastase and reactive oxygen species in the development of lung injury suggesting that enhanced production of elastase inhibitors or oxidant scavenger molecules (such as superoxide dismutase) may have a significant protective effect. Indeed, several elastase inhibitors such as α1-antitrypsin, secretory leucocyte proteinase inhibitor (SLPI), and elastin have been extensively characterised and a gene augmentation approach might logically be expected to tip the inflammatory process in favour of protection rather than excessive tissue injury (fig 1).

**Conclusion**

Historically, emphasis in gene therapy has been directed towards treatment of single gene defects such as cystic fibrosis. We believe, however, that targeted gene therapy may, in the next few years, make a contribution to the treatment options for lung diseases with multifactorial aetiology such as COPD and ARDS. Key factors in the pathogenesis of these conditions have been identified (such as unregulated release of neutrophil elastase) and have suggested which specific genes may be of most therapeutic benefit. However, improvements require to be made in vector design, in ameliorating the specificity and durability of expression, and in manipulating the host immune response. At present liposomes and adenoviruses (or a combination of both) are the preferred vectors for use in the lungs, but if trials prove its safety then adenovirus-associated virus could offer an attractive alternative by virtue of its selective integration site in human chromosome 19, conferring stable and sustainable expression.